Russell Investments Group Ltd. Increases Stock Position in Medpace Holdings, Inc. $MEDP

Russell Investments Group Ltd. raised its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 13.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,509 shares of the company’s stock after acquiring an additional 9,536 shares during the period. Russell Investments Group Ltd.’s holdings in Medpace were worth $24,632,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the company. Jefferies Financial Group Inc. increased its position in shares of Medpace by 20.1% during the second quarter. Jefferies Financial Group Inc. now owns 25,253 shares of the company’s stock worth $7,926,000 after purchasing an additional 4,218 shares in the last quarter. American Century Companies Inc. grew its stake in Medpace by 13.7% during the 2nd quarter. American Century Companies Inc. now owns 12,717 shares of the company’s stock worth $3,991,000 after buying an additional 1,529 shares during the last quarter. Nemes Rush Group LLC grew its stake in Medpace by 8.3% during the 2nd quarter. Nemes Rush Group LLC now owns 628 shares of the company’s stock worth $197,000 after buying an additional 48 shares during the last quarter. Heron Bay Capital Management increased its position in Medpace by 0.3% during the second quarter. Heron Bay Capital Management now owns 19,640 shares of the company’s stock worth $6,164,000 after buying an additional 57 shares during the period. Finally, AXQ Capital LP purchased a new stake in Medpace in the second quarter valued at approximately $217,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Activity

In related news, CEO August J. Troendle sold 59,025 shares of the firm’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the sale, the chief executive officer owned 774,602 shares in the company, valued at $470,787,603.56. This trade represents a 7.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel Stephen P. Ewald sold 15,230 shares of Medpace stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $598.85, for a total value of $9,120,485.50. Following the completion of the sale, the general counsel directly owned 13,343 shares in the company, valued at $7,990,455.55. This represents a 53.30% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 317,597 shares of company stock valued at $189,967,248. Company insiders own 20.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Zacks Research upgraded shares of Medpace from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 27th. Mizuho upped their price target on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research report on Friday, October 24th. Barclays raised their price objective on shares of Medpace from $425.00 to $485.00 and gave the stock an “underweight” rating in a research report on Friday, October 24th. Cowen restated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Finally, Rothschild & Co Redburn downgraded shares of Medpace from a “buy” rating to a “neutral” rating and increased their target price for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $487.18.

Medpace Price Performance

NASDAQ:MEDP opened at $599.50 on Friday. The firm has a market cap of $16.89 billion, a price-to-earnings ratio of 41.92, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42. The firm’s fifty day moving average price is $560.60 and its 200 day moving average price is $444.37. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $626.26.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. During the same quarter in the prior year, the firm earned $3.01 EPS. Medpace’s quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.